|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||627.90 - 638.68|
|52 Week Range||433.52 - 666.65|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||32.11|
|Earnings Date||Jan 31, 2022 - Feb 04, 2022|
|Forward Dividend & Yield||1.04 (0.18%)|
|Ex-Dividend Date||Sep 14, 2021|
|1y Target Est||581.02|
Thermo Fisher Scientific Inc. has completed its $17.5 billion acquisition of Wilmington, N.C.-based contract research organization PPD Inc.
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.